Petri Dishes

Recent News

March 2019

aTen Therapeutics attends Crown Bioscience’s Oncology Drug Discovery Symposium in Cambridge, exploring future approaches to cancer therapies.

February 2019

aTen Therapeutics welcomes Deanna Olubadewo as our new Research Assistant, on a work placement from the University of Edinburgh, via the Santander Universities Scheme.

Overview

Our management team has extensive experience within the biopharmaceutical industry, and a wealth of knowledge in building successful biotechnology companies.

The team was responsible for the formation and subsequent growth of Bioenvision Inc. into a NASDAQ National listed, global biopharmaceutical company, which was acquired by Genzyme Corporation in October 2007.

This experienced management team is now applying its expertise to the growth of aTen Therapeutics and the development of Tensinomab as a new medicine with the potential to treat several serious medical conditions.

A subsidiary of OncoBioPharm Ltd, aTen Therapeutics has recently completed a financing round which will take lead candidate Tensinomab through to clinical trials.

info@atentherapeutics.com

© aTen Therapeutics 2019. All rights reserved